Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM.

Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC.

Nucl Med Biol. 2005 Aug;32(6):623-30.

PMID:
16026709
2.

Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).

Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW.

J Nucl Med. 2006 Jun;47(6):989-98.

3.

Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.

Valtorta S, Belloli S, Sanvito F, Masiello V, Di Grigoli G, Monterisi C, Fazio F, Picchio M, Moresco RM.

J Nucl Med. 2013 Jul;54(7):1106-12. doi: 10.2967/jnumed.112.111120. Epub 2013 May 22.

4.

Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.

Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ.

J Nucl Med. 2001 Apr;42(4):655-61.

5.

Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less ρ0 cells and cybrids carrying MELAS mitochondrial DNA mutation.

Yoshii Y, Yoneda M, Ikawa M, Furukawa T, Kiyono Y, Mori T, Yoshii H, Oyama N, Okazawa H, Saga T, Fujibayashi Y.

Nucl Med Biol. 2012 Feb;39(2):177-85. doi: 10.1016/j.nucmedbio.2011.08.008. Epub 2011 Oct 26.

PMID:
22033022
6.

Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).

Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ.

J Nucl Med. 2008 Feb;49(2):201-5. doi: 10.2967/jnumed.107.048520. Epub 2008 Jan 16.

7.

Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.

Aft RL, Lewis JS, Zhang F, Kim J, Welch MJ.

Cancer Res. 2003 Sep 1;63(17):5496-504.

8.

Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.

Dence CS, Ponde DE, Welch MJ, Lewis JS.

Nucl Med Biol. 2008 Aug;35(6):713-20. doi: 10.1016/j.nucmedbio.2008.06.001.

9.

Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines.

Vāvere AL, Lewis JS.

Nucl Med Biol. 2008 Apr;35(3):273-9. doi: 10.1016/j.nucmedbio.2007.11.012.

10.

Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model.

Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ.

J Nucl Med. 1999 Jan;40(1):177-83.

11.

Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential.

Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A.

J Nucl Med. 1997 Jul;38(7):1155-60.

12.

Demonstration of the retention of 64Cu-ATSM in cardiac myocytes using a novel incubation chamber for screening hypoxia-dependent radiotracers.

Handley MG, Medina RA, Paul RL, Blower PJ, Southworth R.

Nucl Med Commun. 2013 Oct;34(10):1015-22. doi: 10.1097/MNM.0b013e328363f25e.

PMID:
23872986
13.

Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.

Tateishi K, Tateishi U, Sato M, Yamanaka S, Kanno H, Murata H, Inoue T, Kawahara N.

AJNR Am J Neuroradiol. 2013 Jan;34(1):92-9. doi: 10.3174/ajnr.A3159. Epub 2012 Jun 14.

14.

Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia.

McCall KC, Humm JL, Bartlett R, Reese M, Carlin S.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e393-9. doi: 10.1016/j.ijrobp.2012.05.005. Epub 2012 Jun 23.

15.

A comparison of the behavior of (64)Cu-acetate and (64)Cu-ATSM in vitro and in vivo.

Hueting R, Kersemans V, Cornelissen B, Tredwell M, Hussien K, Christlieb M, Gee AD, Passchier J, Smart SC, Dilworth JR, Gouverneur V, Muschel RJ.

J Nucl Med. 2014 Jan;55(1):128-34. doi: 10.2967/jnumed.113.119917. Epub 2013 Dec 12.

16.

Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression.

Liu J, Hajibeigi A, Ren G, Lin M, Siyambalapitiyage W, Liu Z, Simpson E, Parkey RW, Sun X, Oz OK.

J Nucl Med. 2009 Aug;50(8):1332-9. doi: 10.2967/jnumed.109.061879. Epub 2009 Jul 17.

17.

Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG.

Obata A, Yoshimoto M, Kasamatsu S, Naiki H, Takamatsu S, Kashikura K, Furukawa T, Lewis JS, Welch MJ, Saji H, Yonekura Y, Fujibayashi Y.

Nucl Med Biol. 2003 Jul;30(5):529-34.

PMID:
12831991
18.

A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].

Furukawa T, Yuan Q, Jin ZH, Aung W, Yoshii Y, Hasegawa S, Endo H, Inoue M, Zhang MR, Fujibayashi Y, Saga T.

Oncol Rep. 2015 Sep;34(3):1379-87. doi: 10.3892/or.2015.4079. Epub 2015 Jun 25.

PMID:
26134305
19.

Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.

O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL.

Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1493-502.

PMID:
15817355
20.

Cardiac hypoxia imaging: second-generation analogues of 64Cu-ATSM.

Handley MG, Medina RA, Mariotti E, Kenny GD, Shaw KP, Yan R, Eykyn TR, Blower PJ, Southworth R.

J Nucl Med. 2014 Mar;55(3):488-94. doi: 10.2967/jnumed.113.129015. Epub 2014 Jan 13.

Supplemental Content

Support Center